MedTrace Logo

A Clinical Study of ZL-85FA Tablets

NCT07339748 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2026-01-15

No results posted yet for this study

Summary

An open-label, multicenter phase I/IIa clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZL-85FA tablets in treating advanced solid tumors

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

ZL-85FA tablets

Based on the results obtained from the dose escalation phase, the necessity and dosage of the IIa phase expansion cohort will be determined by the Drug Safety Review Committee (SMC) after discussion.

DRUG

ZL-85FA tablets

ZL-85FA tablets 20mg, oral, once daily

DRUG

ZL-85FA tablets

ZL-85FA tablets 25mg, oral, once daily

DRUG

ZL-85FA tablets

ZL-85FA tablets 30mg, oral, once daily

DRUG

ZL-85FA tablets

ZL-85FA tablets 2.5mg, oral, once daily

DRUG

ZL-85FA tablets

ZL-85FA tablets 5mg, oral, once daily

DRUG

ZL-85FA tablets

ZL-85FA tablets 10mg, oral, once daily

DRUG

ZL-85FA tablets

ZL-85FA tablets 15mg, oral, once daily

DRUG

ZL-85FA tablets

Based on the results obtained from the dose escalation phase, the necessity and dosage of the IIa phase expansion cohort will be determined by the Drug Safety Review Committee (SMC) after discussion.

Sponsors & Collaborators

  • Chengdu Zenitar Biomedical Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-06-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07339748 on ClinicalTrials.gov